Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 21, 2025Frontiers in MedicineOpen Access

Efficacy and influencing factors of immunosuppressive therapy combined with or without eltrombopag in children with severe aplastic anemia

View Full Paper
Ask AI
Bookmark
Share

Authors

JGJingchen GaoHYHui YangMLMeiling Liao

Discussion

Loading...

Member takes

Overview

Retrospective study shows immunosuppressive therapy with eltrombopag has similar efficacy to cyclosporine in children with severe aplastic anemia, suggesting safer treatment options.

Key Points

  • This study aims to compare the efficacy of eltrombopag combined with immunosuppressive therapy versus cyclosporine alone in treating severe aplastic anemia in children.
  • Retrospective study with three patient groups: EPAG + rabbit antithymocyte globulin + cyclosporine, EPAG + cyclosporine, and cyclosporine alone.
  • Evaluation of overall remission rates at 1, 3, 6, and 12 months post-treatment.
  • Assessment of adverse reaction rates across the three groups.
  • No significant difference in overall remission rates among the three groups at all evaluated time points.
  • Adverse reaction incidence: 36.4% (EPAG + rabbit antithymocyte globulin + cyclosporine), 58.3% (EPAG + cyclosporine), and 69.2% (cyclosporine alone).
  • Patients with an EPAG initiation ≤60 days post-diagnosis and preserved hematopoietic function showed better response rates.

Cite This Study

Gao et al. (2025) studied this question.

synapsesocial.com/papers/6924e3ecc0ce034ddc34ef0ehttps://doi.org/10.3389/fmed.2025.1688771
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and influencing factors of immunosuppressive therapy combined with or without eltrombopag in children with severe aplastic anemia2025 · 2 citations
  2. 2A Multicenter, Retrospective Study Comparing Immunosuppressive Therapy Combined with Eltrombopag to Immunosuppressive Therapy Alone as Front-Line Treatment for Pediatric Severe Aplastic Anemia.2025 · 2 citations
  3. 3Long-term outcomes in patients with severe aplastic anemia treated with immunosuppression and eltrombopag: a phase 2 study2021 · 111 citations
  4. 4Outcomes of eltrombopag combined with immunosuppressive therapy in adults with severe aplastic anemia: A large, propensity-matched retrospective analysis2025
  5. 5Long-term outcomes of intensive immunosuppressive therapy combined with eltrombopag in patients with severe aplastic anemia2025